Temat: "angiogenesis" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Proof-of-concept calculations to determine the health-adjusted life-year trade-off between intravitreal anti-VEGF injections and transmission of COVID-19.
Autorzy :: Boyd MJ; Adapt Research Ltd, Reefton, New Zealand.
Scott DAR; Department of Ophthalmology, Gisborne Hospital, Hauora Tairāwhiti, Gisborne, New Zealand.
Squirrell DM; Department of Ophthalmology, Greenlane Clinical Centre, Auckland District Health Board, Auckland, New Zealand.
Wilson GA; Department of Ophthalmology, Gisborne Hospital, Hauora Tairāwhiti, Gisborne, New Zealand.; Matai Lab, Gisborne, New Zealand.; Pokaż więcej
Źródło :: Clinical & experimental ophthalmology [Clin Exp Ophthalmol] 2020 Dec; Vol. 48 (9), pp. 1276-1285. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :: Journal Article
MeSH Terms :: Pandemics*
SARS-CoV-2*
Visual Acuity*
Angiogenesis Inhibitors/*adverse effects
COVID-19/*transmission
Disease Transmission, Infectious/*statistics & numerical data
Macular Degeneration/*drug therapy
Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/administration & dosage ; COVID-19/epidemiology ; Comorbidity ; Female ; Humans ; Intravitreal Injections/adverse effects ; Macular Degeneration/epidemiology ; Male ; Middle Aged ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Patient experience of anti-vegf intravitreal injection.
Autorzy :: Gualino V; Clinique Honoré-Cave, 406, boulevard Montauriol, 82000 Montauban, France. Electronic address: .
Fourmaux E; Centre retine gallien, 68, rue du Palais-Gallien, 33000 Bordeaux, France. Electronic address: .
Grenet T; CIL, 11, rue Antoine-Bourdelle 75015 Paris, France. Electronic address: .
Zerbib J; Nice Retina, 5, rue Eugène-Emmanuel, 06000 Nice, France. Electronic address: .
Wolff B; Centre ophtalmologique Maison-Rouge, 6, rue de l'Église, 67000 Strasbourg, France. Electronic address: .; Pokaż więcej
Źródło :: Journal francais d'ophtalmologie [J Fr Ophtalmol] 2020 Dec; Vol. 43 (10), pp. 1047-1053. Date of Electronic Publication: 2020 Sep 28.
Typ publikacji :: Journal Article
MeSH Terms :: Angiogenesis Inhibitors/*administration & dosage
Anxiety/*epidemiology
Intravitreal Injections/*psychology
Macular Degeneration/*drug therapy
Patient Satisfaction/*statistics & numerical data
Stress, Psychological/*epidemiology
Vascular Endothelial Growth Factor A/*immunology
Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/adverse effects ; Anxiety/etiology ; Female ; France/epidemiology ; Humans ; Intravitreal Injections/adverse effects ; Macular Degeneration/epidemiology ; Male ; Middle Aged ; Postoperative Complications/epidemiology ; Postoperative Complications/psychology ; Stress, Psychological/etiology ; Surveys and Questionnaires ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Predictors of good visual outcomes in patients with neovascular age-related macular degeneration in daily practice.
Autorzy :: Prieto-Del-Cura M; Department of ophthalmology, Hospital universitario Del Tajo, Aranjuez, Spain; Universidad Alfonso-X-el-Sabio, Madrid, Spain; Hospital universitario Infanta-Leonor, Madrid, Spain. Electronic address: .
Villafruela-Güemes I; Department of ophthalmology, Hospital universitario Del Tajo, Aranjuez, Spain; Universidad Alfonso-X-el-Sabio, Madrid, Spain.
Recio-Gamo E; Department of ophthalmology, Hospital universitario Del Tajo, Aranjuez, Spain; Universidad Alfonso-X-el-Sabio, Madrid, Spain.
Sastre-Ibañez M; Hospital universitario Infanta-Leonor, Madrid, Spain.
Fuentes-Ferrer ME; Universidad Alfonso-X-el-Sabio, Madrid, Spain; Servicio de medicina preventiva, Hospital clínico San-Carlos, Instituto de investigación sanitaria del Hospital San-Carlos, Madrid, Spain.; Pokaż więcej
Źródło :: Journal francais d'ophtalmologie [J Fr Ophtalmol] 2020 Dec; Vol. 43 (10), pp. 989-995. Date of Electronic Publication: 2020 Oct 17.
Typ publikacji :: Journal Article
MeSH Terms :: Visual Acuity*
Angiogenesis Inhibitors/*administration & dosage
Bevacizumab/*administration & dosage
Macular Degeneration/*drug therapy
Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/adverse effects ; Bevacizumab/adverse effects ; Biomarkers, Pharmacological/analysis ; Female ; Humans ; Intravitreal Injections ; Macular Degeneration/diagnosis ; Macular Degeneration/epidemiology ; Male ; Neovascularization, Pathologic/diagnosis ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/epidemiology ; Practice Patterns, Physicians'/statistics & numerical data ; Prognosis ; Retrospective Studies ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Internalization of HMGB1 (High Mobility Group Box 1) Promotes Angiogenesis in Endothelial Cells.
Autorzy :: Lan J; Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failured Research, Department of Pathophysiology, School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Luo H; Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failured Research, Department of Pathophysiology, School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Wu R; Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failured Research, Department of Pathophysiology, School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Wang J; Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failured Research, Department of Pathophysiology, School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Zhou B; Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failured Research, Department of Pathophysiology, School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Zhang Y; Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failured Research, Department of Pathophysiology, School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Jiang Y; Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failured Research, Department of Pathophysiology, School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Xu J; Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failured Research, Department of Pathophysiology, School of Basic Medical Science, Southern Medical University, Guangzhou, China.; Pokaż więcej
Źródło :: Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2020 Dec; Vol. 40 (12), pp. 2922-2940. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Angiogenesis Inducing Agents/*administration & dosage
Endothelial Progenitor Cells/*metabolism
HMGB1 Protein/*administration & dosage
Ischemia/*drug therapy
Muscle, Skeletal/*blood supply
Neovascularization, Physiologic/*drug effects
Angiogenesis Inducing Agents/metabolism ; Animals ; Biological Transport ; Cells, Cultured ; Disease Models, Animal ; Dynamins/metabolism ; HMGB1 Protein/metabolism ; Hindlimb ; Injections, Intramuscular ; Ischemia/genetics ; Ischemia/metabolism ; Ischemia/physiopathology ; Male ; Mice, Inbred C57BL ; Mice, Knockout ; Receptor for Advanced Glycation End Products/genetics ; Receptor for Advanced Glycation End Products/metabolism ; Regional Blood Flow ; Signal Transduction ; Toll-Like Receptor 2/genetics ; Toll-Like Receptor 2/metabolism ; Toll-Like Receptor 4/genetics ; Toll-Like Receptor 4/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
Autorzy :: Xu J; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Electronic address: .
Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Bai C; Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
Wang W; Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Li J; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Yu X; Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Li Z; Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China.
Li E; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yuan X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chi Y; National Cancer Center and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yin Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lou W; Department of General Surgery, Zhongshan Hospital of Fudan University, Shanghai, China.
Xu N; Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Bai Y; Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Zhang T; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiu D; Department of General Surgery, Peking University Third Hospital, Beijing, China.
Wang X; Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China.
Yuan Y; Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chen J; Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China.
Qin S; People's Liberation Army Cancer Center of Nanjing Jinling Hospital, Nanjing, China.
Jia R; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Lu M; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Cheng Y; Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
Zhou Z; Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Li J; Department of Clinical and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.
He J; Department of Clinical and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.
Su W; Department of Clinical and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.; Pokaż więcej
Źródło :: The Lancet. Oncology [Lancet Oncol] 2020 Nov; Vol. 21 (11), pp. 1489-1499. Date of Electronic Publication: 2020 Sep 20.
Typ publikacji :: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Angiogenesis Inhibitors/*administration & dosage
Drug-Related Side Effects and Adverse Reactions/*pathology
Neuroendocrine Tumors/*drug therapy
Pancreatic Neoplasms/*drug therapy
Adult ; Aged ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; China/epidemiology ; Disease Progression ; Double-Blind Method ; Drug-Related Side Effects and Adverse Reactions/classification ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Neuroendocrine Tumors/epidemiology ; Neuroendocrine Tumors/genetics ; Neuroendocrine Tumors/pathology ; Pancreatic Neoplasms/epidemiology ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/pathology ; Progression-Free Survival ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy-Guided Intravitreal Injections.
Autorzy :: Trivizki O; Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Karp MR; Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Chawla A; Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Yamanuha J; Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA.
Gregori G; Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Rosenfeld PJ; Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: .; Pokaż więcej
Źródło :: American journal of ophthalmology [Am J Ophthalmol] 2020 Nov; Vol. 219, pp. 222-230. Date of Electronic Publication: 2020 Jul 02.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Cost-Benefit Analysis*
Visual Acuity*
Angiogenesis Inhibitors/*therapeutic use
Choroidal Neovascularization/*drug therapy
Physical Examination/*economics
Tomography, Optical Coherence/*economics
Wet Macular Degeneration/*drug therapy
Aged ; Angiogenesis Inhibitors/economics ; Bevacizumab/economics ; Bevacizumab/therapeutic use ; Choroidal Neovascularization/economics ; Cost Savings/economics ; Female ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Mydriatics/administration & dosage ; Pupil/drug effects ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Recombinant Fusion Proteins/economics ; Recombinant Fusion Proteins/therapeutic use ; Retreatment ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Wet Macular Degeneration/economics
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Autorzy :: Xu J; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Electronic address: .
Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Zhou Z; Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Li J; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Bai C; Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
Chi Y; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li Z; Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China.
Xu N; Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Li E; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Liu T; Department of Medical Oncology, Zhongshan Hospital of Fudan University, Shanghai, China.
Bai Y; Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yuan Y; Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Li X; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wang X; Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China.
Chen J; Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China.
Ying J; Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Yu X; Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Qin S; People's Liberation Army Cancer Center of Nanjing Jinling Hospital, Nanjing, China.
Yuan X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhang T; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Deng Y; Department of Medical Oncology, The Sixth Affiliated Hospital, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases l, Sun Yat-sen University, Guangzhou, Guangdong, China.
Xiu D; Department of General Surgery, Peking University Third Hospital, Beijing, China.
Cheng Y; Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
Tao M; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jia R; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Wang W; Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Li J; Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.
Fan S; Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.
Peng M; Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.
Su W; Department of Clinical Development and Regulatory Affairs, Hutchison MediPharma, Shanghai, China.; Pokaż więcej
Źródło :: The Lancet. Oncology [Lancet Oncol] 2020 Nov; Vol. 21 (11), pp. 1500-1512. Date of Electronic Publication: 2020 Sep 20.
Typ publikacji :: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Angiogenesis Inhibitors/*administration & dosage
Drug-Related Side Effects and Adverse Reactions/*pathology
Neuroendocrine Tumors/*drug therapy
Pancreatic Neoplasms/*drug therapy
Adult ; Aged ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; China/epidemiology ; Disease Progression ; Double-Blind Method ; Drug-Related Side Effects and Adverse Reactions/classification ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Neuroendocrine Tumors/epidemiology ; Neuroendocrine Tumors/genetics ; Neuroendocrine Tumors/pathology ; Pancreatic Neoplasms/epidemiology ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/pathology ; Progression-Free Survival ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Anti-angiogenic effects of testis-specific gene antigen 10 on primary endothelial cells.
Autorzy :: Valipour E; Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Nooshabadi VT; Department of Tissue Engineering and Applied Cell Sciences, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Mahdipour S; Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Shabani S; Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Farhady-Tooli L; Department of Microbiology, School of Biology, College of Science, Tehran University, Tehran, Iran.
Majidian S; School of Electrical Engineering, Iran University of Science and Technology, Tehran, Iran.
Noroozi Z; Department of Molecular Medicine, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran, Iran.
Mansouri K; Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Motevaseli E; Department of Molecular Medicine, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran, Iran.
Modarressi MH; Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: .; Pokaż więcej
Źródło :: Gene [Gene] 2020 Sep 05; Vol. 754, pp. 144856. Date of Electronic Publication: 2020 Jun 05.
Typ publikacji :: Journal Article
MeSH Terms :: Cell Movement*
Cell Proliferation*
Neovascularization, Physiologic*
Angiogenesis Inhibitors/*metabolism
Cytoskeletal Proteins/*metabolism
Human Umbilical Vein Endothelial Cells/*cytology
Human Umbilical Vein Endothelial Cells/*metabolism
Angiogenesis Inhibitors/genetics ; Cytoskeletal Proteins/genetics ; Extracellular Signal-Regulated MAP Kinases/genetics ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Humans ; Matrix Metalloproteinases/genetics ; Matrix Metalloproteinases/metabolism ; Mitogen-Activated Protein Kinase 3/genetics ; Mitogen-Activated Protein Kinase 3/metabolism ; Signal Transduction ; Vascular Endothelial Growth Factor Receptor-2/genetics ; Vascular Endothelial Growth Factor Receptor-2/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
Autorzy :: Urakawa H; Department of Orthopaedic Surgery, Nagoya University, Nagoya, Japan.; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Kawai A; Department of Musculoskeletal Oncology, National Cancer Center, Tokyo, Japan.
Goto T; Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Hiraga H; Department of Orthopaedic Surgery, Hokkaido Cancer Center, Sapporo, Japan.
Ozaki T; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Tsuchiya H; Department of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Nakayama R; Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Naka N; Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan.
Matsumoto Y; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
Kobayashi E; Department of Musculoskeletal Oncology, National Cancer Center, Tokyo, Japan.
Okuma T; Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Kunisada T; Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Ando M; Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Ueda T; Department of Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Nishida Y; Department of Orthopaedic Surgery, Nagoya University, Nagoya, Japan.; Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.; Pokaż więcej
Źródło :: Cancer science [Cancer Sci] 2020 Sep; Vol. 111 (9), pp. 3303-3312. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :: Clinical Trial, Phase II; Journal Article
MeSH Terms :: Drug Resistance, Neoplasm*
Angiogenesis Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Sarcoma/*drug therapy
Sarcoma/*pathology
Sulfonamides/*therapeutic use
Adolescent ; Adult ; Aged ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Female ; Humans ; Japan ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Sarcoma/therapy ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Treatment Outcome ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: 2-deoxy-d-ribose (2dDR) upregulates vascular endothelial growth factor (VEGF) and stimulates angiogenesis.
Autorzy :: Dikici S; Department of Materials Science & Engineering, Kroto Research Institute, University of Sheffield, Sheffield, UK.
Bullock AJ; Department of Materials Science & Engineering, Kroto Research Institute, University of Sheffield, Sheffield, UK.
Yar M; Interdisciplinary Research Centre in Biomedical Materials (IRCBM), COMSATS University Islamabad Lahore Campus, Lahore 54000, Pakistan.
Claeyssens F; Department of Materials Science & Engineering, Kroto Research Institute, University of Sheffield, Sheffield, UK.
MacNeil S; Department of Materials Science & Engineering, Kroto Research Institute, University of Sheffield, Sheffield, UK. Electronic address: .; Pokaż więcej
Źródło :: Microvascular research [Microvasc Res] 2020 Sep; Vol. 131, pp. 104035. Date of Electronic Publication: 2020 Jun 25.
Typ publikacji :: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Angiogenesis Inducing Agents/*pharmacology
Chorioallantoic Membrane/*blood supply
Deoxyribose/*pharmacology
Endothelial Cells/*drug effects
Neovascularization, Physiologic/*drug effects
Vascular Endothelial Growth Factor A/*metabolism
Alginates/chemistry ; Angiogenesis Inducing Agents/chemistry ; Animals ; Cells, Cultured ; Chick Embryo ; Delayed-Action Preparations ; Deoxyribose/chemistry ; Drug Carriers ; Drug Stability ; Endothelial Cells/metabolism ; Humans ; Signal Transduction ; Up-Regulation
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: [Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer].
Autorzy :: Wang J; Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Li K; Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.; Pokaż więcej
Źródło :: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2020 Aug 23; Vol. 42 (8), pp. 624-628.
Typ publikacji :: Journal Article
MeSH Terms :: Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Agents/*therapeutic use
Lung Neoplasms/*drug therapy
Neovascularization, Pathologic/*drug therapy
Small Cell Lung Carcinoma/*drug therapy
Angiogenesis Inhibitors/pharmacology ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/pharmacology ; Bevacizumab/pharmacology ; Bevacizumab/therapeutic use ; Humans ; Lung Neoplasms/pathology ; Neovascularization, Pathologic/pathology ; Precision Medicine ; Small Cell Lung Carcinoma/pathology ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.
Autorzy :: Xiao K; First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li FZ; First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Liang SZ; First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wang J; First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Qian C; First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wan GM; First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Pokaż więcej
Źródło :: The Annals of pharmacotherapy [Ann Pharmacother] 2020 Aug; Vol. 54 (8), pp. 750-756. Date of Electronic Publication: 2020 Jan 31.
Typ publikacji :: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :: Drug Substitution*
Angiogenesis Inhibitors/*therapeutic use
Diabetes Mellitus/*drug therapy
Diabetic Retinopathy/*drug therapy
Macular Edema/*drug therapy
Receptors, Vascular Endothelial Growth Factor/*therapeutic use
Recombinant Fusion Proteins/*therapeutic use
Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Bevacizumab/therapeutic use ; Humans ; Intravitreal Injections ; Qualitative Research ; Ranibizumab/administration & dosage ; Ranibizumab/adverse effects ; Ranibizumab/therapeutic use ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/adverse effects ; Reproducibility of Results ; Treatment Outcome ; Visual Acuity
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Changes in metamorphopsia after the treat-and-extend regimen of anti-VEGF therapy for macular edema associated with branch retinal vein occlusion.
Autorzy :: Mori K; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ishikawa K; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Wada I; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kubo Y; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kobayashi Y; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nakama T; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Haruta M; Department of Ophthalmology, Graduate School of Medical Sciences, Kurume University, Kurume, Japan.
Akiyama M; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nakao S; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshida S; Department of Ophthalmology, Graduate School of Medical Sciences, Kurume University, Kurume, Japan.
Sonoda KH; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Pokaż więcej
Źródło :: PloS one [PLoS One] 2020 Oct 28; Vol. 15 (10), pp. e0241343. Date of Electronic Publication: 2020 Oct 28 (Print Publication: 2020).
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Angiogenesis Inhibitors/*therapeutic use
Macular Edema/*complications
Macular Edema/*drug therapy
Retinal Vein Occlusion/*complications
Retinal Vein Occlusion/*drug therapy
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
Vision Disorders/*complications
Aged ; Angiogenesis Inhibitors/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Recurrence ; Vascular Endothelial Growth Factor A/metabolism ; Visual Acuity
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 14 14.

Tytuł :: Nanodelivery of Resveratrol-Loaded PLGA Nanoparticles for Age-Related Macular Degeneration.
Autorzy :: Bhatt P; Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Blvd., MDC30, Tampa, Florida, 33612, USA.
Fnu G; Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Blvd., MDC30, Tampa, Florida, 33612, USA.
Bhatia D; Department of Pharmacogenomics, Bernard J Dunn School of Pharmacy, 8095 Innovation Park Drive, Fairfax, Virginia, 22031-4868, USA.
Shahid A; Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Blvd., MDC30, Tampa, Florida, 33612, USA.
Sutariya V; Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Blvd., MDC30, Tampa, Florida, 33612, USA. .; Pokaż więcej
Źródło :: AAPS PharmSciTech [AAPS PharmSciTech] 2020 Oct 21; Vol. 21 (8), pp. 291. Date of Electronic Publication: 2020 Oct 21.
Typ publikacji :: Journal Article
MeSH Terms :: Nanoparticles*
Angiogenesis Inhibitors/*administration & dosage
Antioxidants/*administration & dosage
Resveratrol/*administration & dosage
Wet Macular Degeneration/*drug therapy
Angiogenesis Inhibitors/pharmacology ; Cell Line ; Cell Survival/drug effects ; Humans ; Intravitreal Injections ; Polymers/metabolism ; Vascular Endothelial Growth Factor A/metabolism ; Visual Acuity
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Ninjurin 1 dodecamer peptide containing the N-terminal adhesion motif (N-NAM) exerts proangiogenic effects in HUVECs and in the postischemic brain.
Autorzy :: Kim SW; Department of Anatomy, Medical Research Center, Inha University School of Medicine, Inharo 100, Inchon, 22202, Republic of Korea.; Medical Research Center, Inha University School of Medicine, Inchon, Republic of Korea.; Department of Biomedical Sciences, Inha University School of Medicine, Inchon, Republic of Korea.
Lee HK; Department of Anatomy, Medical Research Center, Inha University School of Medicine, Inharo 100, Inchon, 22202, Republic of Korea.; Medical Research Center, Inha University School of Medicine, Inchon, Republic of Korea.
Seol SI; Department of Anatomy, Medical Research Center, Inha University School of Medicine, Inharo 100, Inchon, 22202, Republic of Korea.; Medical Research Center, Inha University School of Medicine, Inchon, Republic of Korea.
Davaanyam D; Department of Anatomy, Medical Research Center, Inha University School of Medicine, Inharo 100, Inchon, 22202, Republic of Korea.; Medical Research Center, Inha University School of Medicine, Inchon, Republic of Korea.
Lee H; Department of Anatomy, Medical Research Center, Inha University School of Medicine, Inharo 100, Inchon, 22202, Republic of Korea.; Medical Research Center, Inha University School of Medicine, Inchon, Republic of Korea.
Lee JK; Department of Anatomy, Medical Research Center, Inha University School of Medicine, Inharo 100, Inchon, 22202, Republic of Korea. .; Medical Research Center, Inha University School of Medicine, Inchon, Republic of Korea. .; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2020 Oct 07; Vol. 10 (1), pp. 16656. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Angiogenesis Inducing Agents/*pharmacology
Cell Adhesion Molecules, Neuronal/*pharmacology
Human Umbilical Vein Endothelial Cells/*drug effects
Ischemic Stroke/*drug therapy
Neovascularization, Physiologic/*drug effects
Nerve Growth Factors/*pharmacology
Neuroprotective Agents/*pharmacology
Angiogenesis Inducing Agents/therapeutic use ; Animals ; Brain/drug effects ; Brain/metabolism ; Cell Adhesion Molecules, Neuronal/metabolism ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Disease Models, Animal ; Human Umbilical Vein Endothelial Cells/metabolism ; Humans ; Ischemic Stroke/metabolism ; Nerve Growth Factors/metabolism ; Neuroprotective Agents/therapeutic use ; Neutrophils/drug effects ; Neutrophils/metabolism ; Rats ; Signal Transduction/drug effects
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 16 16.

Tytuł :: Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Autorzy :: Brown GC; Center for Value-Based Medicine, Hilton Head, South Carolina, USA; Wills Eye Hospital, Jefferson Medical University, Philadelphia, Pennsylvania, USA; Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: .
Brown MM; Center for Value-Based Medicine, Hilton Head, South Carolina, USA; Wills Eye Hospital, Jefferson Medical University, Philadelphia, Pennsylvania, USA; Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA.
Rapuano S; Center for Value-Based Medicine, Hilton Head, South Carolina, USA; Wills Eye Hospital, Jefferson Medical University, Philadelphia, Pennsylvania, USA.
Boyer D; Retina-Vitreous Associates Medical Group, Los Angeles, California, USA.; Pokaż więcej
Źródło :: American journal of ophthalmology [Am J Ophthalmol] 2020 Oct; Vol. 218, pp. 225-241. Date of Electronic Publication: 2020 Jun 19.
Typ publikacji :: Comparative Study; Journal Article
MeSH Terms :: Cost-Benefit Analysis*
Angiogenesis Inhibitors/*economics
Choroidal Neovascularization/*economics
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
Vascular Endothelial Growth Factor A/*economics
Wet Macular Degeneration/*economics
Aged ; Angiogenesis Inhibitors/therapeutic use ; Bevacizumab/economics ; Bevacizumab/therapeutic use ; Choroidal Neovascularization/drug therapy ; Drug Costs ; Female ; Health Care Costs ; Humans ; Intravitreal Injections ; Male ; Medicare ; Quality-Adjusted Life Years ; Ranibizumab/economics ; Ranibizumab/therapeutic use ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Recombinant Fusion Proteins/economics ; Recombinant Fusion Proteins/therapeutic use ; United States ; Visual Acuity ; Wet Macular Degeneration/drug therapy
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
Autorzy :: Lestable L; Service d'Ophtalmologie, CHU de Dijon, France. Electronic address: .
Gabrielle PH; Service d'Ophtalmologie, CHU de Dijon, France.
Bron AM; Service d'Ophtalmologie, CHU de Dijon, France; Eye and Nutrition Research Group, CSGA, UMR1324 INRA, 6265 CNRS, Université Bourgogne Franche-Comté, 14, rue Paul-Gaffarel, 21079 Dijon, France.
Nguyen P; The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Creuzot-Garcher C; Service d'Ophtalmologie, CHU de Dijon, France; Eye and Nutrition Research Group, CSGA, UMR1324 INRA, 6265 CNRS, Université Bourgogne Franche-Comté, 14, rue Paul-Gaffarel, 21079 Dijon, France.; Pokaż więcej
Źródło :: Journal francais d'ophtalmologie [J Fr Ophtalmol] 2020 Oct; Vol. 43 (8), pp. 761-769. Date of Electronic Publication: 2020 Jul 01.
Typ publikacji :: Journal Article
MeSH Terms :: Angiogenesis Inhibitors/*administration & dosage
Macular Degeneration/*drug therapy
Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/adverse effects ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Blindness/drug therapy ; Blindness/epidemiology ; Female ; France/epidemiology ; Humans ; Intravitreal Injections ; Macular Degeneration/epidemiology ; Male ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/epidemiology ; Ranibizumab/administration & dosage ; Ranibizumab/adverse effects ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/adverse effects ; Registries ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Fibrovascular pigment epithelial detachment in eyes with subretinal hemorrhage secondary to neovascular AMD or PCV: a morphologic predictor associated with poor treatment outcomes.
Autorzy :: Kim JH; Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4gaYoungdeungpo-gu, Seoul, 150-034, South Korea. .
Kim JY; Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4gaYoungdeungpo-gu, Seoul, 150-034, South Korea.
Lee DW; Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4gaYoungdeungpo-gu, Seoul, 150-034, South Korea.
Kim CG; Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4gaYoungdeungpo-gu, Seoul, 150-034, South Korea.
Kim JW; Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4gaYoungdeungpo-gu, Seoul, 150-034, South Korea.; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2020 Sep 10; Vol. 10 (1), pp. 14943. Date of Electronic Publication: 2020 Sep 10.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Angiogenesis Inhibitors/*administration & dosage
Choroidal Neovascularization/*complications
Retinal Detachment/*pathology
Retinal Hemorrhage/*pathology
Retinal Pigment Epithelium/*pathology
Visual Acuity/*drug effects
Wet Macular Degeneration/*complications
Aged ; Algorithms ; Angiogenesis Inhibitors/adverse effects ; Choroidal Neovascularization/drug therapy ; Female ; Fluorescein Angiography ; Humans ; Intravitreal Injections ; Male ; Prognosis ; Retinal Detachment/etiology ; Retinal Hemorrhage/etiology ; Retinal Pigment Epithelium/drug effects ; Retrospective Studies ; Treatment Outcome ; Wet Macular Degeneration/drug therapy
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 19 19.

Tytuł :: Antiangiogenic effects of AG36, a triterpenoid saponin from Ardisia gigantifolia stapf.
Autorzy :: Mu LH; Medical Supplies Center, Chinese PLA General Hospital, Beijing, 100853, China.
Wang LH; Medical Supplies Center, Chinese PLA General Hospital, Beijing, 100853, China.
Wang YN; First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Liu P; Medical Supplies Center, Chinese PLA General Hospital, Beijing, 100853, China. .
Yan C; Department of Basic Theory of Chinese Medicine, School of Pre-Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510060, China. .; The Research Centre of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510060, China. .; Pokaż więcej
Źródło :: Journal of natural medicines [J Nat Med] 2020 Sep; Vol. 74 (4), pp. 732-740. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji :: Journal Article
MeSH Terms :: Angiogenesis Inhibitors/*therapeutic use
Ardisia/*chemistry
Medicine, Chinese Traditional/*methods
Saponins/*chemistry
Angiogenesis Inhibitors/pharmacology ; Animals ; Humans
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Anticancer Effect of a Spiro-acridine Compound Involves Immunomodulatory and Anti-angiogenic Actions.
Autorzy :: Duarte SS; Post Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, Brazil.
Silva DKF; Post Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, Brazil.
Lisboa TMH; Post Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, Brazil.
Gouveia RG; Post Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, Brazil.
Ferreira RC; Post Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, Brazil.
DE Moura RO; Drug Development and Synthesis Laboratory, Department of Pharmacy, State University of Paraíba, João Pessoa, Brazil.
DA Silva JM; Post Graduation Program in Pharmaceutical Sciences, Federal University of Pernambuco, Recife, Brazil.
DE Almeida Lima É; Multicenter Postgraduate Program in Physiological Sciences, Federal University of Paraíba, João Pessoa, Brazil.
Rodrigues-Mascarenhas S; Post Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, Brazil.; Multicenter Postgraduate Program in Physiological Sciences, Federal University of Paraíba, João Pessoa, Brazil.
DA Silva PM; Department of Molecular Biology, Federal University of Paraíba, João Pessoa, Brazil.
Farias DF; Laboratory of Risk Assessment for Novel Technologies, Department of Molecular Biology, Federal University of Paraiba, João Pessoa, Brazil.
DA Costa Ribeiro Souza JA; Laboratory of Risk Assessment for Novel Technologies, Department of Molecular Biology, Federal University of Paraiba, João Pessoa, Brazil.
DE Paula Medeiros KC; Department of Morphology, Federal University of Rio Grande do Norte, Natal, Brazil.
GonÇalves JCR; Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa, Brazil.
Sobral MV; Post Graduation Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa, Brazil .; Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa, Brazil.; Pokaż więcej
Źródło :: Anticancer research [Anticancer Res] 2020 Sep; Vol. 40 (9), pp. 5049-5057.
Typ publikacji :: Journal Article
MeSH Terms :: Acridines/*pharmacology
Angiogenesis Inhibitors/*pharmacology
Antineoplastic Agents/*pharmacology
Immunologic Factors/*pharmacology
Spiro Compounds/*pharmacology
Acridines/chemistry ; Angiogenesis Inhibitors/chemistry ; Animals ; Antineoplastic Agents/chemistry ; Cell Cycle/drug effects ; Cell Line, Tumor ; Cytokines/metabolism ; Disease Models, Animal ; Humans ; Immunologic Factors/chemistry ; Immunomodulation/drug effects ; Mice ; Molecular Structure ; Spiro Compounds/chemistry ; Xenograft Model Antitumor Assays ; Zebrafish
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""angiogenesis"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język